依达拉奉对脑梗死患者血清基质金属蛋白酶-9及基质金属蛋白酶抑制剂-1的影响

Influence of edaravone on the serum levels of MMP-9 and RIMP-1 in patients with acute cerebral infarction

目的探讨依达拉奉对急性脑梗死患者血清基质金属蛋白酶-9(MMP-9)及基质金属蛋白酶抑制剂-1(TIMP-1)的影响并探讨其作用机制。方法40例急性脑梗死患者随机分成两组,A组(银杏达莫20ml,1次/d,连续14d,静脉点滴);B组(加用依达拉奉注射液30mg,2次/d,连续14d,静脉点滴)。同期选择非脑血管病患者20例作为对照组。检测治疗前和治疗后第7天患者血清MMP-9及TIMP-1浓度的变化,测定治疗前、治疗第30天的NIHSS评分,判定两组的疗效。结果在治疗第7天,B组的MMP-9浓度明显低于A组(P<0.01)。治疗第7天时,与A组相比,B组TIMP-1浓度升高明显(P<0.01)。B组治疗的有效率及显效率明显高于A组(P<0.05)。结论依达拉奉能够直接降低血清MMP-9的浓度,或通过调节TIMP-1来降低MMP-9水平,可能是其有效治疗急性脑梗死的机制之一。

Objective To study the influence of edaravone on the serum levels of MMP-9 and TIMP-1 in patients with acute cerebral infarction. Methods 40 patients with acute cerebral infarction were randomly divided into routine group of 20 cases and Edaravone group of 20 cases. All cases were given routine treatment,and edaravone group were added with edaravone 30mg,twice a day, totally 14d. The serum levels of MMP-9 and TIMP-1 were investigated before and 7d after treatment,and the NIH scale and clinical outcome were evaluated before and 30d after treatment. Results The therapeutic efficacy of edaravone group was significantly better than that of routine group（P 〈 0.05 ）. The serum levels of MMP-9 of the edaravone group was lower than that of routine group after 7d（P 〈 0.01 ）. Compared with routine group,the serum levels of TIMP-1 of the edaravone group was higher after 7d （P 〈 0.01 ）. Conclusion Our result indicates that edaravone can reduce the injury of ischemic brain cells and improve therapeutic efficacy probably through down regulation of serum MMP-9 level or through upregulating TIMP-1 expression to reduce MMP-9 level.